tradingkey.logo
tradingkey.logo
Search

Liminatus Pharma Ord Shs Class A

LIMN
Add to Watchlist
0.104USD
+0.002+1.76%
Close 07-31 16:00ETQuotes delayed by 15 min
4.66MMarket Cap
LossP/E TTM

LIMN Income Statement

You can find the annual or quarterly income statement of Liminatus Pharma Ord Shs Class A here for insights into the performance and operational efficiency of Liminatus Pharma Ord Shs Class A.
Quarterly
Quarterly+Annual
Quarterly
Annual
YOY
Hide blank rows
FY2026Q1
FY2025Q4
FY2025Q3
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021Q4
FY2021Q3
FY2021Q2
FY2021Q1
Operating expenses
--1.10M
69.13%884.21K
-31.24%701.17K
-17.60%522.79K
50.77%1.02M
70.90%642.08K
17.07%721.75K
-51.83%634.43K
310.49%676.32K
28.67%375.70K
5.45%616.49K
-8.88%1.32M
-208.72%-321.30K
-26.12%291.99K
46.88%584.63K
--1.45M
--295.52K
--395.23K
--398.02K
R&D expenses
--400.00K
--0.00
--0.00
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
Depreciation, depletion, and amortization
--518.00
--543.00
--542.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
----
Other operating expenses
----
----
----
-17.60%522.79K
50.77%1.02M
70.90%642.08K
17.07%721.75K
-51.83%634.43K
310.49%676.32K
28.67%375.70K
5.45%616.49K
-8.88%1.32M
-208.72%-321.30K
-26.12%291.99K
46.88%584.63K
--1.45M
--295.52K
--395.23K
--398.02K
Operating profit
---1.10M
-69.13%-884.21K
31.24%-701.17K
17.60%-522.79K
-50.77%-1.02M
-70.90%-642.08K
-17.07%-721.75K
51.83%-634.43K
-310.49%-676.32K
-28.67%-375.70K
-5.45%-616.49K
8.88%-1.32M
208.72%321.30K
26.12%-291.99K
-46.88%-584.63K
---1.45M
---295.52K
---395.23K
---398.02K
Net non-operating interest income (expenses)
Non-operating interest income
--0.00
-100.00%0.00
-100.00%0.00
-48.77%24.13K
-92.18%32.99K
--33.36K
-44.22%47.24K
-98.36%47.09K
1070.61%421.85K
-100.00%0.00
1144.26%84.70K
41753.68%2.87M
535.24%36.04K
3637.89%161.10K
--6.81K
--6.86K
--5.67K
--4.31K
----
Non-operating interest expense
--18.64K
-86.07%19.05K
--19.05K
22.82%136.76K
--0.00
--0.00
--1.34K
--111.35K
----
----
----
----
----
----
----
----
----
----
----
Special income (expenses)
---4.18K
-3061.21%-7.27M
82.50%636.87K
-201.83%-229.84K
861.58%348.97K
-86.85%78.64K
-61.02%-176.53K
119.32%225.70K
-101.82%-45.82K
-84.44%598.18K
-102.50%-109.64K
-199.77%-1.17M
-64.29%2.52M
1572.15%3.84M
380.67%4.39M
--1.17M
--7.05M
--229.86K
---1.57M
Other non-operating income (expenses)
---8.36K
--0.00
---1.74M
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
Income before tax
---1.12M
-844.10%-8.17M
-185.91%-1.82M
-82.93%-865.26K
-112.37%-637.74K
-338.25%-530.07K
-32.89%-852.38K
-222.72%-473.00K
-110.44%-300.29K
-94.01%222.48K
-116.81%-641.43K
243.91%385.44K
-57.48%2.88M
2405.10%3.71M
294.34%3.82M
---267.84K
--6.76M
---161.06K
---1.96M
Income tax
----
-76985.38%-2.35M
----
-77.57%3.05K
-78.12%5.16K
145.52%4.78K
-19.75%5.85K
-96.57%13.60K
-83.58%23.60K
---10.50K
--7.29K
--396.07K
--143.75K
----
----
----
----
----
----
Income after tax
---1.12M
-840.78%-8.17M
-183.61%-1.82M
-78.45%-868.31K
-98.49%-642.90K
-329.57%-534.85K
-32.30%-858.23K
-4474.55%-486.60K
-111.86%-323.89K
-93.72%232.98K
-117.00%-648.72K
96.03%-10.64K
-59.61%2.73M
2405.10%3.71M
294.34%3.82M
---267.84K
--6.76M
---161.06K
---1.96M
Net income from continuous operations
---1.12M
-840.78%-8.17M
-183.61%-1.82M
-78.45%-868.31K
-98.49%-642.90K
-329.57%-534.85K
-32.30%-858.23K
-4474.55%-486.60K
-111.86%-323.89K
-93.72%232.98K
-117.00%-648.72K
96.03%-10.64K
-59.61%2.73M
2405.10%3.71M
294.34%3.82M
---267.84K
--6.76M
---161.06K
---1.96M
Net income attributable to controlling interests
---1.12M
-840.78%-8.17M
-183.61%-1.82M
-78.45%-868.31K
-98.49%-642.90K
-329.57%-534.85K
-32.30%-858.23K
-4474.55%-486.60K
-111.86%-323.89K
-93.72%232.98K
-117.00%-648.72K
96.03%-10.64K
-59.61%2.73M
2405.10%3.71M
294.34%3.82M
---267.84K
--6.76M
---161.06K
---1.96M
Net income attributable to common shareholders
---1.12M
-840.78%-8.17M
-183.61%-1.82M
-78.45%-868.31K
-98.49%-642.90K
-329.57%-534.85K
-32.30%-858.23K
-4474.55%-486.60K
-111.86%-323.89K
-93.72%232.98K
-117.00%-648.72K
96.03%-10.64K
-59.61%2.73M
2405.10%3.71M
294.34%3.82M
---267.84K
--6.76M
---161.06K
---1.96M
Basic earnings per share
---0.03
-295.30%-0.48
21.79%-0.07
-82.65%-0.12
-124.89%-0.09
-365.50%-0.07
-51.17%-0.12
-21406.45%-0.07
-150.33%-0.04
-73.95%0.03
-170.56%-0.08
96.01%0.00
-59.61%0.08
2404.28%0.11
294.34%0.11
---0.01
--0.20
--0.00
---0.06
Diluted earnings per share
---0.03
-295.30%-0.48
21.79%-0.07
-82.65%-0.12
-124.89%-0.09
-365.50%-0.07
-51.17%-0.12
-21406.45%-0.07
-150.33%-0.04
-73.95%0.03
-170.56%-0.08
96.01%0.00
-59.61%0.08
2404.28%0.11
294.34%0.11
---0.01
--0.20
--0.00
---0.06
Dividend per share
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
Currency unit
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
Audit opinions
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----

FAQs

How do I read Liminatus Pharma Ord Shs Class A's income statement on TradingKey?

Start with total revenue, then review cost of revenue, gross profit, operating expenses, operating profit, income before tax, net income, and EPS. Revenue shows the scale of the business, while margins and profit lines show whether that revenue is being converted into earnings efficiently.

What is the difference between quarterly and annual income statements?

A quarterly income statement shows performance for a three-month fiscal period, while an annual income statement summarizes the full fiscal year. Quarterly data is useful for tracking recent momentum and seasonality, while annual data is better for judging long-term growth, profitability, and business cycles.

What does YOY mean on the income statement page?

YOY means year over year. It compares a financial metric with the same period in the previous year, such as this quarter's revenue versus revenue in the same quarter last year. YOY comparison helps investors see growth trends while reducing the impact of normal seasonal changes.

Which income statement metrics matter most when analyzing LIMN stock?

Important metrics include revenue growth, gross profit, gross margin, operating profit, operating margin, net income, EPS, R&D expenses, SG&A expenses, and tax expense. Investors usually look at these together to judge whether the company is growing, controlling costs, and improving profitability.

What was Liminatus Pharma Ord Shs Class A's net income for the year?

Liminatus Pharma Ord Shs Class A posted -10.21M in net income for fiscal year 2025.

How much net income did Liminatus Pharma Ord Shs Class A post in the last quarter?

Liminatus Pharma Ord Shs Class A reported -1.12M in net income for the latest quarter。

What was Liminatus Pharma Ord Shs Class A's annual operating profit?

Liminatus Pharma Ord Shs Class A's operating income was -2.97M for fiscal year 2025.

How is EPS related to the income statement?

EPS, or earnings per share, is based on net income divided by the number of shares outstanding. It helps investors understand how much profit the company generated for each share, but it should be reviewed alongside share count changes, margins, cash flow, and valuation metrics.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.